On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Rasagiline appears to be well tolerated, although elderly patients may be more prone to treatment-emergent adverse cardiovascular and psychiatric effects. At the recommended therapeutic dosage of ...

The latest approval is based on results from the phase 3 NATALEE trial, which showed that the addition of Kisqali to treatment with an AI cut the risk of invasive disease, recurrence, or death ...

There are a wide variety of treatment options to help you lose weight. Treatments include nutrition, exercise, medications, procedures, and other therapies that help people lose excess weight. A ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.